Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning for Allo-HSCT in Older Patients
NCT07052422Phase 3Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of venetoclax and decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Disease-free survival rate at 2 years. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07052422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052422.